​Predicine and CR Medicon form strategic partnership to accelerate global Clinical Trials and Registration Approval

On November 11, 2020, CR Medicon and  Predicine jointly announced that it has entered into a global strategic partnership to assist biomarker-driven clinical trials and novel oncology therapeutics registration in US and China. This strategic partnership will ultimately expedite the clinical development of biopharmaceutical companies' new oncology drugs in US and China, including global clinical trial support, regulatory support, biomarker-driven drug development, and CDx development.

Through this collaboration, CR Medicon will be able to leverage Predicine’s cfDNA + cfRNA liquid biopsy platform to accelerate patient screening and enrollment, and ultimately expedite the clinical development and registration of innovative drugs for the benefit of patients. Predicine and CR Medicon will collaborate on marketing, customer service and patient support in the fields of precision clinical trials and patient screening.

“Biomarker is playing an increasingly important role in precision clinical trials and new drug application”, said Dr. Jia Shidong, founder and CEO of Predicine, “The strategic collaboration between Predicine and CR Medicon will help the multinational pharmaceutical companies speed up global clinical trials and new drug registration and provide cancer patients around the globe with more personalized treatment options as soon as possible.”

Dr. Henry Wu, CEO of CR Medicon, said, “I believe that by combining CR Medicon’s expertise in clinical development and China-U.S. dual registration with Predicine’s expertise in molecular testing, it will be help to the simultaneous advances in personalized drug development and registration in both China and the U.S. formulated by biopharmaceutical companies, thus providing patients with high-quality innovative drugs more quickly and effectively.”

About CR Medicon

CR Medicon, a controlling subsidiary of Pharmaron,is a fast-growing Contract Research Organization (CRO) and a platform providing customers with one-stop services for clinical studies of drugs and devices, including Regulatory Affairs, Medical Strategy, Medical Writing, Medical Monitoring, Pharmacovigilance, Clinical Operations, Data Management, Statistical Analysis and Bioanalytical Laboratory. CR Medicon has provided highquality and reliable clinical development services to nearly 200 pharmaceutical customers world-wide since it was founded more than three years ago. With our professional, rigorous and efficient approach to service and best-in-class integrated resources and systems, CR Medicon helps clients reduce R&D risks, save R&D costs and launch new products quickly and efficiently.

About Predicine

Predicine is a molecular insights company that is committed to advancing biomarker-driven precision medicine. Predicine has developed a breakthrough cell-free RNA- and cell-free DNA-based liquid biopsy technology for non-invasive cancer profiling, disease monitoring and assessing minimal residual disease. The company has launched a portfolio of blood-based and urine-based assays for solid tumors and hematologic malignancies.  Through its CLIA and/or CAP facilities in the US and China, Predicine partners with leading biopharma companies and hospitals to support global clinical trials and personalized cancer therapy.